An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: A pilot study

Journal of Affective Disorders

Volumn 128, Issue 1-2, 2011, Pages 41-48

  Spronk, D ^a   Arns, M ^a,c   Barnett, K J ^b   Cooper, N J ^b   Gordon, E ^b  

^a RESEARCH INSTITUTE BRAINCLINICS   (Netherlands)

^b Brain Resource Company   (Australia)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antidepressant treatment outcome; Biomarkers; ERPs; Major depressive disorder; Neuropsychology; Personalized medicine; QEEG; Single nucleotide polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; CHEEK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; DELTA RHYTHM; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; GENETIC MARKER; GENETIC POLYMORPHISM; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; THETA RHYTHM; TREATMENT OUTCOME; TREATMENT RESPONSE; VERBAL MEMORY;

ADULT; ANTIDEPRESSIVE AGENTS; AUDITORY PERCEPTION; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; COGNITION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; HUMANS; LINEAR MODELS; MALE; MEMORY; METHIONINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; THETA RHYTHM; TREATMENT OUTCOME; VERBAL LEARNING;

EID: 78649639991     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2010.06.021     Document Type: Article

References (50)

1. B. Arias, A. Serretti, C. Lorenzi, C. Gastó, R. Catalán, and L. Fañanás Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin J. Affect. Disord. 90 2-3 2006 251 256
2. M. Arns, J. Gunkelman, M. Breteler, and D. Spronk EEG phenotypes predict treatment outcome to stimulants in children with ADHD J. Integr. Neurosci. 7 3 2008 421 438
3. M. Bares, M. Brunovsky, M. Kopecek, P. Stopkova, T. Novak, J. Kozeny, and C. Höschl Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study J. Psychiatr. Res. 41 3-4 2007 319 325
4. M. Bares, M. Brunovsky, M. Kopecek, T. Novak, P. Stopkova, J. Kozeny, P. Sos, V. Krajca, and C. Höschl Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder Eur. Psychiatry 23 5 2008 350 355
5. B.T. Baune, C. Hohoff, K. Berger, A. Neumann, S. Mortensen, T. Roehrs, J. Deckert, V. Arolt, and K. Dosmscheke Association of the COMT val158met variant with antidepressant treatment response in major depression Neuropsychopharmacology 33 4 2008 924 932
6. F. Benedetti, C. Colombo, A. Pirovano, E. Marino, and E. Smeraldi The catechol-O-methyltransferase (Val(108/158) Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting Psychopharmacology Berl. 203 1 2009 155 160
7. F. Benedetti, B. Barbini, A. Bernasconi, M.C. Fulgosi, S. Dallaspezia, C. Gavinelli, C. Locatelli, C. Lorenzi, A. Pirovano, D. Radaelli, E. Smeraldi, and C. Colombo Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val (108/158)Met polymorphism J. Affect. Disord. 121 1-2 2010 68 72
8. H.R. Bogner, M.L. Bruce, C.F. Reynold III, B.H. Mulsant, M.S. Cary, K. Morales, G.S. Alexopoulos PROSPECT group The effects of memory, attention, and executive dysfunction on outcomes of depression in a primary care intervention trial: the PROSPECT study Int. J. Geriatr. Psychiatry 22 9 2007 922 929
9. G.E. Bruder, C.E. Tenke, J.W. Stewart, J.P. Towey, P. Leite, M. Voglmaier, and F.M. Quitkin Brain event-related potentials to complex tones in depressed patients: relations to perceptual asymmetry and clinical features Psychophysiology 32 4 1995 373 381
10. G.E. Bruder, C.E. Tenke, J.W. Stewart, P.J. McGrath, and F.M. Quitkin Predictors of therapeutic response to treatments for depression: a review of electrophysiologic and dichotic listening studies CNS Spectr. 9 1999 30 36
11. G.E. Bruder, J.W. Stewart, C.E. Tenke, P.J. McGrath, P. Leite, N. Bhattcharya, and F.M. Quitkin Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant Biol. Psychiatry 49 5 2001 416 425
12. G.E. Bruder, J.P. Sedoruk, J.W. Stewart, P.J. McGrath, F.M. Quitkin, and C.E. Tenke Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post- treatment findings Biol. Psychiatry 63 12 2008 1171 1177
13. B. Chen, D. Dowlatshahi, G.M. MacQueen, J.F. Wang, and L.T. Young Increased hippocampal BDNF immunoreactivity in participants treated with antidepressant medication Biol. Psychiatry 50 4 2001 260 265
14. M.J. Choi, R.H. Kang, S.W. Lim, K.S. Oh, and M.S. Lee Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder Brain Res. 1118 1 2006 176 182
15. C.R. Clark, R.H. Paul, L.M. Williams, M. Arns, K. Fallahpour, C. Handmer, and E. Gordon Standardized assessment of cognitive functioning during development and aging using an automated touchscreen battery Arch. Clin. Neuropsychol. 21 5 2006 449 467
16. I.A. Cook, and A.F. Leuchter Prefrontal changes and treatment response prediction in depression Semin. Clin. Neuropsychiatry 6 2 2001 113 120
17. I.A. Cook, A.F. Leuchter, M. Morgen, E. Witte, W.F. Stubbeman, M. Abrams, S. Rosenberg, and S.H. Uijtdehaage Early changes in prefrontal activity characterize clinical responders to antidepressants Neuropsychopharmacology 27 1 2002 120 131
18. P. Danos, S. Kasper, H.P. Scholl, J. Kaiser, S. Ruhrmann, G. Höflich, and H.J. Möller Clinical response to sleep deprivation and auditory-evoked potentials-preliminary results Pharmacopsychiatry 27 2 1994 70 71
19. K. Domschke, B. Lawford, G. Laje, K. Berger, R. Young, P. Morris, J. Deckert, V. Arolt, F.J. McMahon, and B.T. Baune Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response Int. J. Neuropsychopharmacol. 23 2009 1 9
20. J.J. Dunkin, A.F. Leuchter, I.A. Cook, J.E. Kasl-Godley, M. Abrams, and S. Rosenberg-Thompson Executive dysfunction predicts nonresponse to fluoxetine in major depression J. Affect. Disord. 60 1 2000 13 23
21. E. Gordon, and L.M. Konopka Integrative neuroscience: the role of a standardized database Clin. EEG Neurosci. 36 2 2005 64 75
22. M. Gorlyn, J.G. Keilp, M.F. Grunebaum, B.P. Taylor, M.A. Oquendo, G.E. Bruder, J.W. Stewart, G. Zalsman, and J.J. Mann Neuropsychological characteristics as predictors of SSRI treatment response in depressed participants J. Neurol. Transm. 115 8 2008 1213 1219
23. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
24. U. Hegerl, R. Bottlender, J. Gallinat, H.J. Kuss, M. Ackenheil, and Möller The serotonin syndrome scale: first results on validity Eur. Arch. Psychiatry Clin. Neurosci. 248 2 1998 96 103
25. I. Herrera-Guzmán, E. Gudayol-Ferré, J. Lira-Mandujano, J. Herrera-Abarca, D. Herrera-Guzmán, K. Montoya-Pérez, and J. Guardia-Olmos Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder Psychiatry Res. 160 1 2008 72 82
26. G. Juckel, O. Pogarell, H. Augustin, C. Mulert, F. Müller- Siecheneder, T. Frodl, P. Mavrogiorgou, and U. Hegerl Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder J. Clin. Psychiatry 68 8 2007 1206-1012
27. B. Kalayam, and G.S. Alexopoulos Prefrontal dysfunction and treatment response in geriatric depression Arch. Gen. Psychiatry 56 8 1999 713 718
28. A.H. Kemp, E. Gordon, A.J. Rush, and L.M. Williams Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures CNS Spectr. 13 12 2008 1066 1086
29. V.J. Knott, J.I. Telner, Y.D. Lapierre, M. Browne, and E.R. Horn Quantitative EEG in the prediction of antidepressant response to imipramine J. Affect. Disord. 39 3 1996 175 184
30. V. Knott, C. Mahoney, S. Kennedy, and K. Evans Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome Pharmacopsychiatry 33 6 2000 201 205
31. A.F. Leuchter, I.A. Cook, R.B. Lufkin, J. Dunkin, T.F. Newton, J.L. Cummings, J.K. Mackey, and D.O. Walter Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography Neuroimage 1 3 1994 208 219
32. A. Marie-Mitchell, A.F. Leuchter, C.P. Chou, W. James Gauderman, and S.P. Azen Predictors of improved mood over time in clinical trials for major depression Psychiatr. Res. 127 1-2 2004 73 84
33. F.J. McMahon, S. Buervenich, D. Charney, R. Lipsky, A.J. Rush, A.F. Wilson, A.J. Sorant, G.J. Papanicolaou, G. Laje, M. Fava, M.H. Trivedi, S.R. Wisniewski, and H. Manji Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Am. J. Hum. Genet. 78 5 2006 804 814
34. M.J. Millan Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 110 2 2006 135 370
35. C. Mulert, G. Juckel, M. Brunnmeier, S. Karch, G. Leicht, R. Mergl, H.J. Möller, U. Hegerl, and O. Pogarell Prediction of treatment response in major depression: integration of concepts J. Affect. Disord. 98 3 2007 215 225
36. S.R. Paige, D.F. Fitzpatrick, J.P. Kline, S.E. Balogh, and S.E. Hendricks Event-related potential amplitude/intensity slopes predict response to antidepressants Neuropsychobiology 30 4 1994 197 201
37. S.R. Paige, S.E. Hendricks, D.F. Fitzpatrick, S. Balogh, and W.J. Burke Amplitude/Intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder Psychopharmacol. Bull. 31 2 1995 243 248
38. E.J. Peters, S.L. Slager, G.D. Jenkins, M.S. Reinalda, H.A. Garriock, S.I. Shyn, J.B. Kraft, P.J. McGrath, and S.P. Hamilton Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response Pharmacogenet. Genomics 19 1 2009 1 10
39. D. Pizzagalli, R.D. Pascual-Marqui, J.B. Nitschke, T.R. Oakes, C.L. Larson, H.C. Abercrombie, S.M. Schaefer, J.V. Koger, R.M. Benca, and R.J. Davidson Anterior cingulated activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis Am. J. Psychiatry 158 3 2001 405 415
40. R.J. Porter, P. Gallagher, J.M. Thompson, and A.H. Young Neurocognitive impairment in drug-free patients with major depressive disorder Br. J. Psychiatry 182 2003 214 220
41. Schafer "Analysis of incomplete multivariate data" 1997 Chapman & Hall London 1997
42. D.V. Sheehan, Y. Lecrubierm, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry. 59 1998 Suppl 20:22-33;quiz 34-57
43. D. Spronk, M. Arns, A. Bootsma, R. van Ruth, and P.B. Fitzgerald Long-term effects of left frontal rTMS on EEG and ERPs in patients with depression Clin. EEG Neurosci. 39 3 2008 118 124
44. A. Szegedi, D. Rujescu, A. Tadic, M.J. Muller, R. Kohnen, H.H. Stassen, and N. Dahmen The catechol-O-methyltransferase Val 108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression Pharmacogenomics J. 5 1 2005 49 53
45. B.P. Taylor, G.E. Bruder, J.W. Stewart, P.J. McGrath, J. Halperin, H. Ehrlichman, and F.M. Quitkin Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients Am. J. Psychiatry 163 2006 73 78
46. S.J. Tsai, C. Cheng, Y.W. Yu, T.J. Chen, and C.J. Hong Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response Am. J. Med. Genet. Neuropsychiatr. Genet. 123B 1 2003 19 22
47. S.J. Tsai, Y.T. Gau, C.J. Hong, Y.J. Liou, Y.W. Yu, and T.J. Chen Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients J. Affect. Disord. 113 1-2 2009 183 187
48. P. Weiland-Fiedler, K. Erickson, T. Waldeck, D.A. Luckenbaugh, D. Pike, O. Bonne, D.S. Charney, and A. Neumeister Evidence for continuing neuropsychological impairments in depression J. Affect. Disord. 82 2 2004 253 258
49. J.B. Williams A structured interview guide for the Hamilton Depression Rating Scale Arch. Gen. Psychiatry 45 8 1988 742 747
50. L.M. Williams, E. Simms, C.R. Clark, R.H. Paul, D. Rowe, and E. Gordon The test-retest reliability of a standardized neurocognitive and neurophysiological test battery: "neuromarker" Int. J. Neurosci. 115 12 2005 1605 1630